Begins Coverage on BIOLASE (NASDAQ:BIOL)

Equities research analysts at began coverage on shares of BIOLASE (NASDAQ:BIOLGet Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the medical technology company’s stock.

A number of other research analysts also recently commented on the company. Maxim Group downgraded BIOLASE from a “strong-buy” rating to a “hold” rating in a report on Friday, May 24th. Benchmark reissued a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a report on Tuesday, May 14th.

Read Our Latest Analysis on BIOLASE

BIOLASE Stock Performance

BIOL stock opened at $0.09 on Friday. BIOLASE has a 1 year low of $0.04 and a 1 year high of $10.31. The firm has a market cap of $3.01 million, a P/E ratio of -0.01 and a beta of 0.71. The stock has a 50-day simple moving average of $0.14 and a 200-day simple moving average of $0.36.

BIOLASE (NASDAQ:BIOLGet Free Report) last issued its quarterly earnings results on Monday, May 13th. The medical technology company reported ($0.36) EPS for the quarter. The business had revenue of $10.13 million during the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%.

Hedge Funds Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC grew its position in shares of BIOLASE, Inc. (NASDAQ:BIOLFree Report) by 1,068.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.79% of the company’s stock.


(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Further Reading

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with's FREE daily email newsletter.